Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 268

Sort by

Sort Order Select

Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood (2024) 144 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2024-206538

Published: 2024

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, Wenyi Fan, Sara M. Tinsley-Vance, Amy E. DeZern, Hetty E. Carraway, Marlise R. Luskin, Gail J. Roboz, Onyee Chan, Aaron T. Gerds, Andrew T. Kuykendall, David P. Steensma, Maria Balasis, Jeffrey E Lancet, Qianxing Mo, Mikkael A. Sekeres, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 6750.

https://doi.org/10.1182/blood-2024-211137

Published: 2024

Journal Articles

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1 ) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Yazan F Madanat, Amir T. Fathi, Guillermo Garcia-Manero, Gail J. Roboz, Justin M. Watts, Gabrielle T. Prince, Praneeth Baratam, Stephane De Botton, Anthony S. Stein, James M. Foran, Martha L. Arellano, David Sallman, Yuanye (Vickie) Zhang, Stephanie M. Kapsalis, Prapti A. Patel, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2024-204862

Published: 2024

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Jorge E. Cortes, Justin M. Watts, Eunice S. Wang, Jay Yang, Shira N. Dinner, Maria R. Baer, Gail J. Roboz, William B. Donnellan

Blood (2024) 144 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2024-204039

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 214.

https://doi.org/10.1182/blood-2024-198218

Published: 2024

Journal Articles

Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Gail J. Roboz, Ahmed Aribi, Adrian Ochsenbein, Carsten Riether, Monic J. Stuart, Emily Mitchell, Komal Changela, Adam George, Michael Boyiadzis, Clayton Smith, Thomas Pabst

Blood (2024) 144 (Supplement 1): 1504.2.

https://doi.org/10.1182/blood-2024-202648

Published: 2024

Journal Articles

Blinded Ex-Vivo testing in AML Reveals Differences between Hypomethylating Agents When Combined with Venetoclax

Dunay Bach, Lía Buffa, Paula Scaglia, Agustina Garcia-Melani, Sharmaine Griffith-Baker, Tarek Ali Zaki, Gastón Soria, Gail J. Roboz

Blood (2024) 144 (Supplement 1): 7492.

https://doi.org/10.1182/blood-2024-210073

Published: 2024

Journal Articles

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Blood (2024) 144 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2024-210134

Published: 2024

Journal Articles

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Gail J. Roboz, Nuria Mencia-Trinchant, Gabriela Pereira, Ellen K. Ritchie, Justin D. Kaner, Michael Samuel, Michal Bar-Natan, Jonathan Canaani, Sharmaine Griffith-Baker, Pinkal Desai, Monica L Guzman

Blood (2024) 144 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2024-212090

Published: 2024

Journal Articles

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet, Neela Easwar, Akriti G. Jain, Madelyn Burkart, Xiaoyue Ma, Paul Christos, Ellen K. Ritchie, Michael Samuel, Justin D. Kaner, Jonathan Canaani, Aaron D. Goldberg, Shira N. Dinner, Kendra L. Sweet, Gail J. Roboz, Pinkal Desai

Blood (2024) 144 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2024-206340

Published: 2024

Journal Articles

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes, Gail J. Roboz, Justin M. Watts, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice Mims

Blood (2024) 144 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2024-201710

Published: 2024

Journal Articles

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2024-199170

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Eunice S. Wang, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Andrew H Wei, Jay Yang, Joseph G Jurcic, Gail J. Roboz, Karen Seiter, Alice Mims, Karen Yee, Brent Ferrell, Shira N. Dinner, William B. Donnellan, William Blum, Francois Di Trapani, Hua Tian, Stephane De Botton

Blood (2024) 144 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2024-198504

Published: 2024

Journal Articles

How I use Maintenance Therapy in Acute Myeloid Leukemia

Gail J. Roboz, Jonathan Canaani

Blood blood.2024024010.

https://doi.org/10.1182/blood.2024024010

Published: 2024

Journal Articles

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Guillermo Garcia-Manero, Olatoyosi Odenike, Shaun Fleming, Gail J. Roboz, Meagan Jacoby, Ilona Cunningham, Karl-Anton Kreuzer, Anoop K Enjeti, Maria R. Baer, Rachel Cook, Joseph Jurcic, Grace Ku, Ying Zhou, David Hoffman, Jalaja Potluri, Jacqueline S. Garcia

Blood (2023) 142 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2023-187102

Published: 2023

Journal Articles

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Gail J. Roboz, Janelle Meyer, Winny Chan, Beloo Mirakhur, Yuri Sano, Aram Oganesian, Harold N. Keer, Michael R. Savona

Blood (2023) 142 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2023-178024

Published: 2023

Journal Articles

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

David L. Grinblatt, Gail J. Roboz, Daniel A. Pollyea, Mikkael A. Sekeres, Bart L. Scott, Karen Seiter, Amer M. Zeidan, Jay L. Patel, Guillermo Garcia-Manero, Rami S. Komrokji, Michael R. Savona, Irene S. Degutis, Pavel Kiselev, Edward Yu, Willem Heydendael, Ying Qiu, Sara Vergara, Ali McBride, Harry P. Erba

Blood (2023) 142 (Supplement 1): 593.

https://doi.org/10.1182/blood-2023-189963

Published: 2023

NARROW

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1 ) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Blinded Ex-Vivo testing in AML Reveals Differences between Hypomethylating Agents When Combined with Venetoclax

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

How I use Maintenance Therapy in Acute Myeloid Leukemia

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only